{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/psoriasis/prescribing-information/dithranol-short-contact/","result":{"pageContext":{"chapter":{"id":"302b90f5-e0d6-53cc-88ce-6a06def02b51","slug":"dithranol-short-contact","fullItemName":"Dithranol (short-contact)","depth":2,"htmlHeader":"<!-- begin field 29e97347-c9b1-4f05-956f-b19553486063 --><h2>Dithranol (short-contact)</h2><!-- end field 29e97347-c9b1-4f05-956f-b19553486063 -->","summary":"","htmlStringContent":"<!-- begin item 2a00a97c-6f2d-4224-a544-7fe509e13e2b --><!-- end item 2a00a97c-6f2d-4224-a544-7fe509e13e2b -->","topic":{"id":"a3ecec3a-acde-5ece-90b0-dedc6c08db8b","topicId":"c8702cb0-6f30-44e4-832b-ab9161ee384a","topicName":"Psoriasis","slug":"psoriasis","lastRevised":"Last revised in December 2020","chapters":[{"id":"d0c39045-d8df-5a7e-bd7d-96fef3aefc3a","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"6e22adaa-de33-5d1c-bc1f-9740d238c5a2","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"a7c9da10-9760-5143-bf20-167f1e832103","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"409aaeee-7f7b-53cc-afdc-9ea9034984d6","slug":"changes","fullItemName":"Changes"},{"id":"1677a6dc-645a-58fe-8ed8-8bdfcface768","slug":"update","fullItemName":"Update"}]},{"id":"ca38cddf-4680-5dc4-a0df-79ab9910a789","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"fc350387-9e56-5f4b-b454-3cfa5ecd9a2a","slug":"goals","fullItemName":"Goals"},{"id":"00a9f2b3-e7b5-5394-9762-48d34a0dc722","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"400cbb71-cb76-5ee3-824a-738bc6249b3b","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"ad046045-038c-5b75-8f42-50343d5b824e","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"773d3740-99b6-5a32-b555-968b2efb0b8b","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"0692cf2f-4b3d-5098-afe3-ac07b3c763ff","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d16fcd88-1021-5238-86e4-2452eee7fdde","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"ef476810-392e-5b83-b527-fe921221cc0b","slug":"definition","fullItemName":"Definition"},{"id":"fb1e0af3-fd46-562a-83d6-33a31640b639","slug":"prevalence","fullItemName":"Prevalence"},{"id":"d6b8dab4-762f-5e9e-a83e-35a3652483b3","slug":"trigger-factors","fullItemName":"Trigger factors"},{"id":"70837c8d-73ae-5bc4-a042-949d31503ca3","slug":"associated-conditions","fullItemName":"Associated conditions"},{"id":"e90f3736-0e28-53fa-8295-309df8aa8e00","slug":"complications","fullItemName":"Complications"},{"id":"9523ad16-6e73-50ba-94bd-64c548f5c313","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"4d0deda5-f89f-59e7-8978-1c3337afdcfe","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"067d150c-d6d4-5992-9319-f86bfeecca88","slug":"assessment","fullItemName":"Assessment"},{"id":"58b4da96-dda6-596b-9570-fd5070898cfe","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"27af05e5-54bf-5bc5-ba76-d1b8f18e7252","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"eaab9e94-c74e-5c84-ba14-d8db3a6dd1e8","fullItemName":"Management","slug":"management","subChapters":[{"id":"82ee7501-0589-54c2-8df7-5a9256a3f1d0","slug":"pustular-or-erythrodermic-psoriasis","fullItemName":"Scenario: Pustular or erythrodermic psoriasis"},{"id":"e4183760-c129-567e-9211-cef27ef68100","slug":"trunk-limbs","fullItemName":"Scenario: Trunk and limbs"},{"id":"6a7e9d56-0d17-5c90-b835-822367fbcd3e","slug":"scalp-psoriasis","fullItemName":"Scenario: Scalp psoriasis"},{"id":"9c7cebad-a77f-5fa8-811a-50815577a51c","slug":"facial-flexural/genital-psoriasis","fullItemName":"Scenario: Facial/flexural/genital psoriasis"},{"id":"6fbadcef-730e-5874-97ad-53e1f12bd5e3","slug":"guttate-psoriasis","fullItemName":"Scenario: Guttate psoriasis"},{"id":"a069495e-d2fe-5fca-9799-1b5f4f874033","slug":"nail-psoriasis","fullItemName":"Scenario: Nail psoriasis"},{"id":"08dc9427-b5ec-59f4-b47b-72a666beacef","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"ce3be64b-a968-59e2-b206-5a055de98330","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"520d3bb6-49cf-5f46-b761-9df1c712ad28","slug":"emollients","fullItemName":"Emollients"},{"id":"2a68bcd1-b92f-579a-955e-f4638d00073f","slug":"vitamin-d-preparations","fullItemName":"Vitamin D preparations"},{"id":"39f1a594-6e44-59b9-bb85-a277475d7386","slug":"salicylic-acid","fullItemName":"Salicylic acid"},{"id":"325d4c77-192a-5152-971f-a5f4f1d64fc7","slug":"coal-tar-products","fullItemName":"Coal tar products"},{"id":"302b90f5-e0d6-53cc-88ce-6a06def02b51","slug":"dithranol-short-contact","fullItemName":"Dithranol (short-contact)"}]},{"id":"00678b76-cc05-5d69-a6be-8760727fb9cf","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"91ae130b-06c7-538c-a295-af4bf7a3dbf1","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"358d84df-224b-5d6b-96cd-c52dfe00a200","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"383c93f2-ae1f-5c75-af43-3a9a448c1669","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"3703e9fb-0103-5fe6-a0ed-192226578ed6","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d248a57f-2b73-5c2f-89c5-18ed618c3535","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"e35fcef8-37a3-5afe-9250-f527d2c6e017","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"7314bc52-4cb9-530c-a905-917edad0de05","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"ce3be64b-a968-59e2-b206-5a055de98330","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"50182cac-95e0-5788-9c03-fc2b6e3fac8d","slug":"availability-choice","fullItemName":"Availability and choice","depth":3,"htmlHeader":"<!-- begin field 20803f3a-3cad-4b67-846e-6cc977f15c30 --><h3>Availability and choice</h3><!-- end field 20803f3a-3cad-4b67-846e-6cc977f15c30 -->","summary":"","htmlStringContent":"<!-- begin item e9047629-8421-4374-9b6d-aa5be2fabcf2 --><!-- begin field 9bc0d1fc-cb12-4ba6-bfbe-8c184232e503 --><ul><li>Dithranol treatments are available as branded and non-branded products (dithranol ointment [BP] and paste [BP]). Branded preparations are most suitable and include:<ul><li>Dithrocream<sup>®</sup> (dithranol 0.1%, 0.25%, 0.5%, 1%, and 2%).</li><li>Micanol<sup>®</sup> cream (dithranol 1% and 3%).</li><li>Psorin<sup>®</sup> scalp gel (dithranol 0.25%, salicylic acid 1.6%).</li></ul></li><li>Creams are particularly suitable because they wash off more easily than ointments.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">BNF 73, 2017</a>]</p><!-- end field 9bc0d1fc-cb12-4ba6-bfbe-8c184232e503 --><!-- end item e9047629-8421-4374-9b6d-aa5be2fabcf2 -->","subChapters":[]},{"id":"38a20e8a-70f5-5377-921d-c57a6eb88e60","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field f8be27dd-c0ad-41a6-9020-1b3e4f878cef --><h3>Contraindications and cautions</h3><!-- end field f8be27dd-c0ad-41a6-9020-1b3e4f878cef -->","summary":"","htmlStringContent":"<!-- begin item 1aeec913-d6eb-4c3b-b640-4fc057908ff7 --><!-- begin field 2293118e-631b-49b5-887c-065ae447acf5 --><p><strong>Do not prescribe dithranol to people with:</strong></p><ul><li>Acute or pustular psoriasis, or inflamed psoriasis.</li><li>Facial psoriasis.</li><li>Sensitive areas of skin.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">BNF 73, 2017</a>] </p><!-- end field 2293118e-631b-49b5-887c-065ae447acf5 --><!-- end item 1aeec913-d6eb-4c3b-b640-4fc057908ff7 -->","subChapters":[]},{"id":"3bb05bc1-88e1-5373-8343-276de77913e5","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field bb1aecf4-5c18-4e5b-aa8e-43278cdd6a48 --><h3>Adverse effects</h3><!-- end field bb1aecf4-5c18-4e5b-aa8e-43278cdd6a48 -->","summary":"","htmlStringContent":"<!-- begin item ba601f9e-7589-403d-8c32-6a7595fc99fd --><!-- begin field 77a556ad-7254-44e3-9470-45a6121f7b47 --><ul><li>Dithranol may cause adverse effects such as:<ul><li>Skin irritation, burning sensation (if left on the skin for too long).</li><li>Staining of the skin, hair, or fabrics (temporary effect).</li><li>Staining of fabric and bathroom fittings (permanent effect).</li></ul></li><li>There are no known adverse effects of dithranol use in pregnancy and breastfeeding.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">BNF 73, 2017</a>] </p><!-- end field 77a556ad-7254-44e3-9470-45a6121f7b47 --><!-- end item ba601f9e-7589-403d-8c32-6a7595fc99fd -->","subChapters":[]},{"id":"d74b387b-c0cb-5af3-8201-ee1f869aa9a9","slug":"application","fullItemName":"Application","depth":3,"htmlHeader":"<!-- begin field 2ab20f7e-3cc4-4c2e-829b-a26f050d1d97 --><h3>Application</h3><!-- end field 2ab20f7e-3cc4-4c2e-829b-a26f050d1d97 -->","summary":"","htmlStringContent":"<!-- begin item e35f7640-2ac9-42a2-be54-4260eb4323b3 --><!-- begin field d82a8a59-0863-476d-89e3-9365484efa8d --><ul><li>Treatment with dithranol should start with the lowest strength (0.1%) cream and gradually increase over about four weeks to the highest tolerated strength that produces the optimum therapeutic effect. Clinical improvement may take up to six weeks.<ul><li>Dithranol cream should be applied once a day to psoriasis areas only (avoid application to normal skin between plaques), to avoid excessive skin irritation.</li><li>The cream is left on for 30–60 minutes, and then washed off.</li><li>This is continued for at least one week, and if necessary increased at weekly intervals to the 0.25% strength, followed by the 0.5%, the 1.0%, and finally the 2.0% strength.</li><li>Note: the optimum strength varies from person to person and depends on the thickness of the plaques and the person's tolerance to adverse effects.</li></ul></li><li>If the areas being treated become inflamed, stop the treatment. When the inflammation settles, restart the treatment at a lower concentration.</li><li>If an emollient is being used, the person should apply this first and then wait 30 minutes before applying the dithranol (only after the emollient has been fully absorbed).</li><li>Once lesions are palpably flat, dithranol should be discontinued.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">BNF 73, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">ABPI, 2014</a>] </p><!-- end field d82a8a59-0863-476d-89e3-9365484efa8d --><!-- end item e35f7640-2ac9-42a2-be54-4260eb4323b3 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}